U.S. FDA rejects expanded indication for Regenron's gout drug
15:51 EDT 30 Jul 2012 | Reuters
July 30 (Reuters) - U.S health regulators have denied approval to Regeneron Pharmaceuticals Inc's experimental drug to prevent gout flares, dashing the hopes of the company of expanding usage of the drug that is already on the market for another ind..
Original Article: U.S. FDA rejects expanded indication for Regenron's gout drug
More From BioPortfolio on "U.S. FDA rejects expanded indication for Regenron's gout drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
